Introduction
Necrotizing enterocolitis (NEC) is among the most common, devastating, and difficult to treat diseases in preterm neonates [1] . The mean prevalence of the disorder is about 7% among infants with a birth weight between 500 and 1,500 g in the USA and Canada based on multicenter neonatal databases [2, 3] . The estimated rate of death associated with NEC ranges between 20 and 30% [4] , with a significant risk of long-term neurodevelopmental consequences [5] . The pathophysiology of NEC is multifactorial, which renders prediction of risk a major challenge [6] [7] [8] [9] [10] .
There have been several studies of diagnostic biomarkers [6, [11] [12] [13] [14] but an effective predictive approach re-
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Methods

Study Design and Sample Collection
This study was approved by the investigational review board of the University of Florida. IRB# is 386-2008 and the period of this study was 2010-2013. Preterm infants with birth weights ≤ 1,250 g and gestational ages ≤ 32 weeks from three University of Florida affiliated hospitals were screened for study enrollment. Informed consent was obtained from the parents of infants that met inclusion criteria. Infants with congenital malformations, congenital conditions of the intestine or lethal conditions were excluded. Only patients with radiologic signs or direct intraoperative confirmation of intestinal pathology were considered to have met the criteria for diagnosis of NEC [1, 18] . Control infants were matched to NEC infants using gestational age, birth weight, center, and date of birth ±2 months.
The phase 1 discovery study involved proteomic profiling, LC-MS/MS protein identification and preliminary Western blot validation of candidate biomarkers in pooled buccal swab samples from 3 time-points, collected 3 weeks, 2 weeks and 1 week prior to the development of NEC on 3 NEC (n = 3) and 3 control (n = 3) infants.
In phase 2, further validation was done using Western blot on an additional 10 NEC and 10 matched controls with buccal samples collected but not pooled 3 weeks, 2 weeks and 1 week before the onset of NEC.
Buccal samples were collected at weekly intervals by placing and twisting a Cytobrush Collector (CooperSurgical Inc., Trumbull, Conn., USA) 360° on both cheeks and the tongue to maximize protein collected. The brush was then washed into 1 ml phosphatebuffered saline and then immediately placed in -80 ° C for later analysis. Protein labeling with CyDye was performed using the CyDye technology (GE Healthcare, Pittsburgh, Pa., USA). Equal amounts (100 μg) of Cy3-control, Cy5-NEC, and Cy2-reference mixture were loaded per polyacrylamide gel (Jule, Inc., Milford, Conn., USA) in Ettan Daltsix Unit from GE.
Immediately after gel electrophoresis, gels were scanned using a Typhoon 9400 Variable Mode Imager (GE). The image acquired was analyzed with DeCyder 2D software (GE). In the biological variation analysis, a master gel was created with information from all gels to provide statistical data on differential protein expression levels between control and NEC groups. 2,000 spots were detected and matched. Interested spots were selected by setting the fold difference threshold to 1.5-fold (NEC/control after normalized). A pick list was made and statistical confidence when two-sided Student's t test p value was <0.05.
Protein Spot Excision and Protein Identification
The information obtained from DeCyder software was transferred to an automated ProPic spot picker (Genomic Solutions, Ann Arbor, Mich., USA) and was submitted for protein identification using LC-MS/MS. LC-MS/MS analysis was carried out on a LTQ Orbitrap XL mass spectrometer (Thermo Scientific, Bremen, Germany). All MS/MS spectra were analyzed using Mascot software, version 2.2.2 (Matrix Science, London, UK). Scaffold-02-03-01 (Proteome Software, Inc., Portland, Oreg., USA) was used to validate MS/MS-based peptide and protein identifications [19] .
Database Mining -System Biology Approach PANTHER bioinformatics software (Protein ANalysis THrough Evolutionary Relationships, University of Southern California, Los Angeles, Calif., USA) was used for gene ontology classification utilizing the human protein ontology database to classify proteins into distinct categories of molecular functions and biological processes [20] . Pathway Studio software version 8.0 (Ariadne Genomics, Rockville, Md., USA) was used to construct pathways and identify altered protein interaction maps along with determining cellular localization of differential proteins.
Western Blot To validate the findings from proteomic analysis, the same protein extracts used for 2D-DIGE were analyzed using Western blotting.
Equal amounts of protein were loaded to each well and separated on 4-20% acrylamide SDS-PAGE gels (Bio-Rad Laboratories, Hercules, Calif., USA) and transferred to PVDF membranes. After blocking, three separate blots were probed using different antibodies (all 1: 1,000; Abcam, Cambridge, Mass., USA) for interleukin-1 receptor antagonist (IL-1RA), peroxidorexin 1 or α 1 -antitrypsin, respectively. Secondary antibodies, ECL Plex goat anti-rabbit Cy5 or goat anti-mouse Cy5 (1: 3,000; GE Healthcare) were incubated with the blots. Images of blots were captured by a Murgas Torrazza et al. 
Phase 2: Validation Study
Two additional validation experiments were performed on samples collected 2-3 weeks and 1 week prior to onset of NEC from 10 NEC babies and 10 matched control infants. Western blots were used to evaluate IL-1RA, peroxiredoxin-1 or α 1 -antitrypsin as described above.
Statistical Methods
Comparisons between NEC versus matched controls were done on three candidate biomarkers: IL-1RA, α 1 -antitrypsin, and peroxiredoxin via one sample two-sided t tests. These were selected from a wider battery of markers from 3 other patients, as described elsewhere in this article. As this is a pilot study, we consider those with p < 0.10 worthy of future study. The planned sample size (n = 10) was not based on a power analysis, but rather on what could be accomplished in the intended time frame.
Results
Clinical Characteristics
Clinical characteristics were compared between control and NEC infants, including birth weight, gestational age, Apgar scores, type of milk, mode of delivery, prenatal steroids exposure, maternal antibiotic exposure, and mode of ventilator support. There were no significant differences between NEC infants and controls (p > 0.05). Table 1 shows data for the second phase validation study.
Predictive Biomarkers Discovery
2D gel analysis and LC-MS/MS of NEC buccal protein levels yielded a total of 21 (8 increased and 13 decreased, all p < 0.05) altered differential protein spots compared to controls. We identified 3 biomarkers of special interest that were of high quality and had a high fold difference between NEC and controls; 1 downregulated protein, IL-1RA and 2 upregulated proteins, peroxiredoxin-1 and α 1 -antitrypsin ( table 2 ). These 3 proteins were validated using Western blot for the same samples that were used for proteomics analysis (cf. online suppl. tables 1 & 2, www.karger.com/doi/10.1159/000353721). Only IL-1RA showed statistical difference (p < 0.05, data not shown).
Systems Biology Approach
A bioinformatics analysis explored if our 2D-based findings would pinpoint specific pathways or classes of proteins altered in NEC. This resulted in 80 assignments for biologic processes, 38 assignments for molecular function and these were sorted into 6 and 12 categories, respectively ( fig. 1 a, b) . The percentages listed are calculated as the number of proteins associated with a particular functional block normalized to the total number of proteins. Altered proteins belonging to different structural and functional families regulate different biological processes in the development of NEC.
The network mapped altered cell processes and pathways regulated by the identified (increased and decreased) proteins. Several processes central to the pathogenesis of NEC were identified, including inflammation, oxidative stress, cell migration, and apoptosis ( fig. 2 ) . Of the identified proteins, 13 were shown to regulate the inflammation-related processes (complement activation, neutrophil accumulation and inflammation activation; fig. 3 a) , among these proteins are the 3 we subsequently validated by Western blot (peroxiredoxin-1, IL-1RA, and α 1 -antitrypsin). NEC associated oxidative stress response related to 13 proteins (7 increased and 6 decreased) ( fig. 3 b) .
Western Blot Analysis
To confirm our findings from the first part of the study, Western blots were performed for the same 3 target proteins on time-point samples of an additional 10 NEC and 10 matched controls. IL-1RA showed a trend to be lower in NEC infants compared to controls within 2-3 weeks prior to the onset of NEC (p = 0.08, fig. 4 a) . However, no differences were seen in samples 1 week prior to the onset of NEC (data not shown). α 1 -Antitrypsin also showed a trend to be lower in the NEC infants compared to controls 1 week (p = 0.06, fig. 4 b) but not 2-3 weeks prior to the onset of the disease. Peroxiredoxin-1 did not show promising results in 1 week ( fig. 4 c, p = 0.48) and 2-3 weeks (data not shown) prior to NEC.
Discussion
The ability to predict a high propensity for the development of NEC could be lifesaving in preterm infants. We collected samples in a non-invasive manner and subjected them to proteomics analysis. There were several proteins that differed prior to the onset of NEC could potentially serve as predictive biomarkers. By using a systems biology approach, we evaluated molecular and biologic functions and cellular localization of identified proteins, and then created a map identifying the networks and pathways of proteins of interest. Finally, to evaluate the validity of our approach and confirm proteomic results, we did Western blots on 3 proteins that were our best targets as putative biomarkers of NEC, including peroxiredoxin-1, IL-1RA, and α 1 -antitrypsin. Peroxiredoxin is an antioxidant that reduces hydroxyperoxides and peroxynitrites [22] . α 1 -Antitrypsin is a protease inhibitor that protects tissues from enzymes of the inflammatory cells [23] . IL-1RA binds the cell surface IL-1 receptor, preventing IL-1 from sending a proinflammatory signal to that cell. IL-1β is especially germane to the pathophysiology of NEC because it causes an increase in intestinal epithelia tight junction permeability [24] , which is thought to be an antecedent to NEC. Furthermore, IL-1β has been found associated with NEC lesions in a piglet model [25] . IL-1RA was decreased prior to the onset of NEC in the NEC group when compared to controls in our preliminary study of pooled samples and it showed a trend to be lower in the NECs compared to controls in the validation part of our study within 2-3 weeks prior to the development of NEC, suggesting that low levels of this particular protein may play an active role in NEC and may serve as a candidate biomarker for additional validation for the prediction of infants at risk for NEC. However, peroxiredoxin-1 and α 1 -antitrypsin did not show significant changes between NEC and controls. It has been suggested that the development of noninvasive biomarkers to help predict and prevent disease in neonates represents a significant need [6] . Using a proteomic approach, a recent study suggested the novel ApoSAA score to help differentiate and diagnose NEC and sepsis [13] . However the study was limited to diagnosis at the time of NEC or sepsis presentation and did not distinguish NEC from sepsis. In our study, 5 out of 10 NEC patients also had positive blood cultures, but the diagnosis of sepsis was either made several days later after the diagnosis of NEC or from blood cultures drawn at the moment of the diagnosis of NEC; 80% had negative blood cultures before NEC. In another study [11] , a non-invasive approach used urine samples from infants at risk for the development of NEC. This study identified urinary I-FABP, claudin-3, and calprotectin as potential diagnostic markers, but not as predictive biomarkers of NEC.
In our current study, we tested a non-invasive method of swabbing the buccal epithelium for proteomic analysis. Obtaining biologic material by swabbing the buccal epithelium in at-risk neonates provides a novel way to investigate the complex physiology likely occurring prior to the onset of NEC. Being non-invasive, this collection method should allow investigators to evaluate the intestine (since the buccal epithelium and intestinal epithelium are from the similar embryologic origins).
Using a proteomic approach, we characterized several biomarker candidates from buccal swabs of very low birth weight neonates. We utilized 2-DIGE results to map global interactions that identified a number of NEC-relevant pathways (inflammation, colorectal cancer, oxidative stress, and chemotaxis, etc.). Two major pathways (inflammation and oxidative stress) were involved in NEC pathogenesis. A sub-network-enriched analysis showed that there are 13 proteins involved in the inflammatory process ( fig. 3 a) which was mapped to inflammation, complement activation and neutrophil accumulation. Similarly, 13 proteins were shown to be regulating the dynamics of oxidative stress response either by activation and/or inhibition which has a major implication on the cell death process ( fig. 3 b) .
In conclusion, using a non-invasive method and a proteomic approach, we identified several proteins that are altered prior to the onset of NEC in susceptible neonates. Thorough analysis of these proteins revealed their molecular functions, biologic functions, and we were able to map the pathways in which these proteins are involved. IL-1RA, according to these preliminary studies, appears to be a promising candidate for additional studies. Currently, we are enrolling patients into a larger study that will provide us with additional samples for validation of these biomarkers.
